. 2020 Oct 31;16(4):543–559. doi: 10.1007/s11302-020-09732-z

Table 4.

In vivo plasma and brain pharmacokinetic parameters of AST-004 in mice following intraperitoneal or intravenous administration of either MRS2365 or AST-004

Compound administered	Compound monitored	Route of administration	Dose (mg/kg; μmol/kg)	Tissue	Pharmacokinetic parameters
Compound administered	Compound monitored	Route of administration	Dose (mg/kg; μmol/kg)	Tissue	C₀ or Cmax (ng/mL or ng/g)	CLp (mL/min/kg)	Vd_ss (L/kg)	AUC (ng-h/mL)	T1/2 (h)
MRS2365	AST-004	I.P.	0.27; 0.5	Plasma	64.5	-	-	29.3^b	0.3
MRS2365	AST-004	I.P.	0.27; 0.5	Brain	6.2	-	-	1.7^c	-
AST-004	AST-004	I.P.	0.15; 0.5	Plasma	49.5	-	-	30.1^b	0.3
AST-004	AST-004	I.P.	0.15; 0.5	Brain	3.2	-	-	1.2^c	-
AST-004	AST-004	I.V.^a	0.25; 0.8	Plasma	115	132	2.2	31.6^b	0.5

Results are the means of 3 mice per timepoint

^aLLOQ for AST-004 plasma was 0.1 ng/mL

^bAUC (0-Inf)

^cAUC (0–0.5 h)

-Not determined